Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG STML-701-0114

Title
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
Principal Investigator
Jeffrey Raizer
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG STML-701-0114
Purpose
The goal of this research study is to find out if SL-701 is safe and tolerable and what effect it has on brain tumors.
Overview
SL-701 is an experimental medication. This means that the United States Food and Drug Administration (FDA) has not approved SL-701. SL-701 is a type of anti-cancer vaccine made up of parts of 3 different short proteins called “peptides” which are also found in certain brain tumors. The vaccine is intended to activate the immune system to recognize and kill the brain tumor cells that have the same protein.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have tumor recurrence (cancer came back) or progression (cancer is worsening)after initial (first) treatment.
  • Participants who received prior cancer chemotherapy with bevacizumab or other VEGF?VEGFR-directed agents (check with the study doctor for any exclusions) cannot participate in this study.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive SL-701 as a vaccine (shot by needle) along with medications that will make the immune response stronger. These medications are referred to as adjuvants. The adjuvant medications are FDA approved. Participants will come in every 2 weeks for 22 weeks and then about once a month after that. Participants will remain on the study until their tumor gets worse or the study doctor feels it is in their best interest to stop.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 20-Dec-14 06:23 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.